# Introducing the first and only prefilled insulin pen that has half-unit dosing measurement[1†]


Humalog® Junior KwikPen®

insulin lispro (rDNA origin) injection
100 units/mL

**NEW** Humalog® Junior KwikPen® (100 units/mL) allows patients to dial their dose to the nearest 0.5 units[1]

The **lightest, shortest** half-unit dosing insulin pen available[2†]

The **newest** in the line of KwikPen devices[3†]


## Ordering information

| UPC for 5-pack | DIN | Item code |
|---|---|---|
| 773007000587 | 02470152 | HP7714 |

* Clinical significance has not been established.
† Comparative clinical significance has not been established.

**Indication:**
HUMALOG (insulin lispro injection) is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. HUMALOG insulins are also indicated for the initial stabilization of diabetes mellitus. HUMALOG is a short acting insulin analogue and is for use in conjunction with a longer acting insulin, such as HUMULIN N (insulin isophane (rDNA origin) NPH), except when used in a subcutaneous insulin infusion pump.

**Contraindications:**
- During episodes of hypoglycemia
- Patients sensitive to insulin lispro or its excipients

**Most serious warnings and precautions:**
**Hypoglycemia:** Uncorrected hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma or even death.

**Administration:**
- Give within 15 minutes before a meal; when necessary, HUMALOG may be given within 20 minutes of the start of the meal.
- Humalog 100 units/mL should not be diluted or mixed with any other insulin when used in a pump.
- Any change of insulin or human insulin analogue should be made cautiously and only under medical supervision.
- Do not use HUMALOG if it is not water clear and colourless or if it has formed a deposit of solid particles on the wall of the vial or cartridge.

**Other relevant warnings and precautions:**
- Hypokalemia may be relevant in patients who are on potassium lowering drugs or losing potassium through other means
- Stress and concomitant illness may change insulin requirements
- To avoid transmission of disease, a cartridge or prefilled syringe should not be used by more than one person
- Any rapid- or short-acting insulin formulation should be used with caution in patients with gastroparesis
- The combination of insulin with a thiazolidinedione is not indicated for the treatment of type 2 diabetes mellitus
- Patients taking a HUMALOG insulin may require a change in dosage from that used with their usual insulins
- Hypoglycemia may occur if the insulin dose is too high in relation to insulin requirement
- Hyperglycemia may occur in conditions of inadequate dosing or discontinuation of HUMALOG and if left untreated may lead to diabetic ketoacidosis or coma which are potentially fatal
- Impaired hepatic function may require careful glucose monitoring
- Local/systemic allergic reactions
- Antibody production may cause hypo- or hyperglycemia in very rare cases
- Renal impairment may reduce insulin requirements
- Patients should be fully informed about potential advantages and disadvantages of HUMALOG
- Insulin requirements may vary during trimester in pregnant women
- The use of HUMALOG in nursing women has not been studied; nursing patients may require dose adjustments
- Dose selection for an elderly patient should take into consideration the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy
- Control of diabetes mellitus may be further complicated by diseases such as acromegaly, Cushing's syndrome, hyperthyroidism and pheochromocytoma
- Regular blood glucose self-monitoring should be considered to obtain optimal glycemic control; glycosylated hemoglobin should be measured every 3 to 4 months in all patients taking insulin products

**For more information:**
Please consult the product monograph at www.lilly.ca/humalogpm/en for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling us at 1-888-545-5972.

**References: 1.** Eli Lilly Medical/Regulatory attestation letter. February 27, 2018. **2.** Data on file, Assessment of Humalog KwikPen Junior, Luxura HD, Novo Nordisk NovoPen Echo® and Sanofi JuniorStar™ Pens. **3.** Eli Lilly Medical/Regulatory attestation letter. April 4, 2018. **4.** Humalog® Product Monograph, Eli Lilly Canada Inc., November 28, 2017.



PAAB
MEMBER OF INNOVATIVE MEDICINES CANADA
PP-HI-CA-0104
Lilly